Analytical Services provides analytical testing and support for drug development from early stage research through commercialization. This includes API and drug product testing, method development and validation, stability testing, physical and chemical characterization, and analytical support for clinical trials. Analytical Services has over 150 analysts and state-of-the-art laboratories and equipment to meet all analytical needs throughout drug development.
The document outlines key aspects of analytical quality by design for pharmaceutical methods and products. It discusses analytical method classifications, parameters for validation, terminology, and international guidelines. Quality by design aims to minimize variability and improve quality through understanding sources of error, selectivity, method transfers, and controlling critical method parameters.
Scale of Science In Pharmaceutical Developmentsatenvish
This document discusses pre-formulation studies in pharmaceutical development. It begins by welcoming the audience and introducing Christopher Lipinski and his influential "Rule of Five" for drug candidate screening. It then provides an overview of the scale of science involved in pre-formulation and early process development activities. Several key aspects of pre-formulation are examined in more detail, including Lipinski's Rule of Five analysis, challenges in dosage form development, influencing parameters, and characteristics of ideal drug candidates. The objectives and components of pre-formulation are outlined.
Medical drug discovery strategy powerpoint ppt templates.SlideTeam.net
The drug discovery process begins with screening 10,000 to 20,000 candidate drugs through high-throughput screening and target validation. Promising candidates then undergo lead optimization using combinatorial chemistry and structure-based drug design. Finally, drugs must pass ADMET studies and clinical trials to receive FDA approval, with only about 1 drug in 10,000 reaching the market.
Medical drug discovery process powerpoint presentation slides.SlideTeam.net
The document describes the drug discovery process. It involves 10,000 to 20,000 candidate drugs being screened through high throughput screening and target validation. The leads then undergo optimization through combinatorial chemistry and structure-based drug design. Finally, the drug candidates proceed to ADMET studies, clinical trials, and FDA approval process with the goal of bringing one approved drug to market.
Medical drug discovery strategy powerpoint presentation templates.SlideTeam.net
The drug discovery process begins with screening 10,000 to 20,000 candidate drugs through high-throughput screening and target validation. Promising candidates then undergo lead optimization using combinatorial chemistry and structure-based drug design. Finally, drugs must pass ADMET studies and clinical trials to receive FDA approval, with only about 1 drug in 10,000 reaching the market.
Medical drug discovery strategy powerpoint presentation slides.SlideTeam.net
The document describes the drug discovery process. It involves 10,000 to 20,000 candidate drugs being screened through high throughput screening and target validation. The leads then undergo optimization through combinatorial chemistry and structure-based drug design. Finally, the drug candidates proceed to ADMET studies, clinical trials, and FDA approval process with the goal of bringing one approved drug to market.
This white paper aims to provide a comprehensive
overview of the CMC guidance by the U.S. Food and Drug
Administration and present a streamlined approach for
development and manufacture of nasal spray products
This document provides guidelines for developing specifications for new drug substances and products according to ICH Q6A. It discusses universal and specific tests/criteria that should be included for drug substances and products, such as identification, description, assay, impurities, dissolution, disintegration, content uniformity, and microbial limits. The document gives acceptance criteria and justification for key tests like dissolution, discussing how to set Q values and limits based on biobatch results and BCS classification. It also provides guidance on other tests for oral liquids, parenterals and solid dosage forms.
The document outlines key aspects of analytical quality by design for pharmaceutical methods and products. It discusses analytical method classifications, parameters for validation, terminology, and international guidelines. Quality by design aims to minimize variability and improve quality through understanding sources of error, selectivity, method transfers, and controlling critical method parameters.
Scale of Science In Pharmaceutical Developmentsatenvish
This document discusses pre-formulation studies in pharmaceutical development. It begins by welcoming the audience and introducing Christopher Lipinski and his influential "Rule of Five" for drug candidate screening. It then provides an overview of the scale of science involved in pre-formulation and early process development activities. Several key aspects of pre-formulation are examined in more detail, including Lipinski's Rule of Five analysis, challenges in dosage form development, influencing parameters, and characteristics of ideal drug candidates. The objectives and components of pre-formulation are outlined.
Medical drug discovery strategy powerpoint ppt templates.SlideTeam.net
The drug discovery process begins with screening 10,000 to 20,000 candidate drugs through high-throughput screening and target validation. Promising candidates then undergo lead optimization using combinatorial chemistry and structure-based drug design. Finally, drugs must pass ADMET studies and clinical trials to receive FDA approval, with only about 1 drug in 10,000 reaching the market.
Medical drug discovery process powerpoint presentation slides.SlideTeam.net
The document describes the drug discovery process. It involves 10,000 to 20,000 candidate drugs being screened through high throughput screening and target validation. The leads then undergo optimization through combinatorial chemistry and structure-based drug design. Finally, the drug candidates proceed to ADMET studies, clinical trials, and FDA approval process with the goal of bringing one approved drug to market.
Medical drug discovery strategy powerpoint presentation templates.SlideTeam.net
The drug discovery process begins with screening 10,000 to 20,000 candidate drugs through high-throughput screening and target validation. Promising candidates then undergo lead optimization using combinatorial chemistry and structure-based drug design. Finally, drugs must pass ADMET studies and clinical trials to receive FDA approval, with only about 1 drug in 10,000 reaching the market.
Medical drug discovery strategy powerpoint presentation slides.SlideTeam.net
The document describes the drug discovery process. It involves 10,000 to 20,000 candidate drugs being screened through high throughput screening and target validation. The leads then undergo optimization through combinatorial chemistry and structure-based drug design. Finally, the drug candidates proceed to ADMET studies, clinical trials, and FDA approval process with the goal of bringing one approved drug to market.
This white paper aims to provide a comprehensive
overview of the CMC guidance by the U.S. Food and Drug
Administration and present a streamlined approach for
development and manufacture of nasal spray products
This document provides guidelines for developing specifications for new drug substances and products according to ICH Q6A. It discusses universal and specific tests/criteria that should be included for drug substances and products, such as identification, description, assay, impurities, dissolution, disintegration, content uniformity, and microbial limits. The document gives acceptance criteria and justification for key tests like dissolution, discussing how to set Q values and limits based on biobatch results and BCS classification. It also provides guidance on other tests for oral liquids, parenterals and solid dosage forms.
Effective process validation contributes significantly to assuring drug quality. The basic
principle of quality assurance is that a drug should be produced that is fit for its intended use.
This principle incorporates the understanding that the following conditions exist:
• Quality, safety, and efficacy are designed or built into the product.
• Quality cannot be adequately assured merely by in-process and finished-product
inspection or testing
Drug discovery process powerpoint presentation templatesSlideTeam.net
The drug discovery process involves several steps:
1) Discovery of 10,000-20,000 candidate drugs through high-throughput screening and target validation.
2) Lead optimization of candidate drugs using combinatorial chemistry and structure-based drug design.
3) ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) studies are conducted on the optimized leads.
One drug is finally approved through clinical trials and NDA (New Drug Application) approval.
This document discusses compendial testing, which involves analytical testing to prove the identity, efficacy, and safety of drug products. It provides examples of identification tests for several active pharmaceutical ingredients (APIs) and their formulated products. Identification tests may use techniques like infrared spectroscopy, thin layer chromatography, melting point determination, or X-ray diffraction to confirm the identity of an API. Tests for formulated products often involve extracting the API from the dosage form. Identification of counterions like chloride or tartrate is also sometimes required for APIs. The level of testing depends on the drug's characteristics and dosage form.
This document outlines chemistry, manufacturing, and controls (CMC) requirements for a marketing authorization application of a drug product. It identifies several areas that require further information, clarification, or validation for the drug substance, excipients, manufacturing process, process controls, specifications, and analytical procedures. Key issues noted include a lack of justification for excipient use, incomplete pharmaceutical development reports, missing process validation data, insufficient characterization of impurities, and non-compliance of some specifications and analytical methods with pharmacopeial standards. Additional data is requested to address these deficiencies before the application can be filed.
This document discusses the process validation of transdermal drug delivery systems. It begins by defining transdermal drug delivery systems as patches designed to deliver medication through the skin. It then lists some advantages and disadvantages of these systems. The document outlines the key elements that must be considered for transdermal validation, including planning, documentation, understanding processes, and communication. It describes the specific unit operations and materials used in transdermal system production like material receipt, mixing, coating, drying, laminating, and pouching. The document also discusses qualification of equipment and processes, assumptions that must be in place before validation, and the documentation required as part of the validation matrix, including the validation protocol.
A seminar on applications of various analytical techniquePatel Parth
This document provides information on preformulation studies for new drug development. It discusses:
1. The purpose of preformulation studies is to understand the characteristics of drug components and optimize dosage form manufacturing.
2. Preformulation studies establish the identity, properties, and compatibility of new drug substances to support formulation development and regulatory filings.
3. A variety of analytical techniques are used in preformulation studies including spectroscopy, chromatography, and thermal analysis to characterize drug substances and excipients.
This document discusses process validation for liquid oral dosage forms. It defines process validation and explains that it ensures consistent production of products meeting quality standards. The objectives are to assure product quality and reduce batch variation. Types of liquid orals include solutions, suspensions, and emulsions. Critical process parameters for equipment, processing, and acceptance criteria are identified. The validation operations described include testing of raw materials and monitoring of outputs like appearance, pH, and content uniformity. A validation report is prepared and changes may require revalidation.
The document discusses pharmaceutical product development and regulation. It addresses what information a regulatory authority would need to see if someone claims to have discovered a new drug or developed a generic version of an existing drug. It explains the importance of absorption and bioavailability/bioequivalence testing. It also presents scenarios about an innovator changing a drug's formulation, manufacturing site, process, or equipment and asks what type of studies would be required. The overall message is that understanding a product, controlling the manufacturing process, and demonstrating consistent quality and therapeutic effect through clinical and comparative dissolution studies are crucial aspects of drug regulation.
This document provides test methods for analyzing phthalate content in children's products used by the U.S. Consumer Product Safety Commission (CPSC). It describes sample preparation, phthalate extraction, gas chromatography-mass spectrometry operating procedures, quality control measures, and calculations for determining phthalate concentration. Comments on the methods are encouraged by March 31, 2009. The general approach is to grind samples, dissolve in solvents, filter, dilute, and analyze by GC-MS, integrating peak areas to quantify six regulated phthalates.
The principal objective of dosage form design is to
achieve a predictable therapeutic response to a drug
included in a formulation which is capable of large scale
manufacture with reproducible product quality. To ensure
product quality, numerous features are required, like
chemical and physical stability, suitable preservation
against microbial contamination if appropriate,
uniformity of dose of drug, acceptability to users
including prescriber and patient, as well as suitable
packing, labeling, and validation1
.
Process validation establishes the flexibility and
constraints in the manufacturing process controls in the
attainment of desirable attributes in the drug product
while preventing undesirable properties. This is an
important concept, since it serves to support the
underlying definition of validation, which is a systematic
approach to identifying, measuring, evaluating,
documenting, and re-evaluating a series of critical steps in
the manufacturing process that require control to ensure
a reproducible final product.3
USFDA defined process validation as “establishing
documented evidence which provides high degree of
assurance that a specific process will consistently produce
a product meeting its pre determined specifications and
quality characteristics.”5
Solid dosage forms include tablets and capsules. The
manufacturing of solid dosage forms involves extensive
powder handling. The powder must be blended for
uniformity and converted into the dosage form either
through compression or encapsulation. Typical
requirements include weighing, blending,
mixing/granulation areas, compression/encapsulation
areas, and coating areas. 2
Despite the ongoing development of more sophisticated
solid drug delivery systems, tablets are still by far the
most prevalent solid dosage form. The emphasis will be
on the practical inspectional requirement, rather than on
a theoretical approach that does not reflect the
practicalities (and problems) encountered when
validating actual production operations.
A tablet is a pharmaceutical dosage form. It comprises a
mixture of active substances and excipients, usually in
powder form, pressed or compacted into a solid. The
excipients can include binders, glidants (flow aids) and
lubricants to ensure efficient tabletting; disintegrants to
promote tablet break-up in the digestive tract;
sweeteners or flavors to enhance taste; and pigments to
make the tablets visually attractive. A polymer coating is
often applied to make the tablet smoother and easier to
swallow, to control the release rate of the active
ingredient, to make it more resistant to the environment
(extending its shelf life), or to enhance the tablet's
appearance
FDA container closure system & drug stability saurav anand 23 iiphncsaurav
The document provides guidelines on container closure systems for packaging drugs and their stability according to FDA regulations. It defines packaging components and discusses CGMP, CPSC, and USP requirements. The guidelines specify information to submit to the FDA regarding packaging qualification, drug dosage forms, and extraction studies. It also addresses post-approval packaging changes, drug master files, bulk containers, and factors that influence drug stability as per ICH guidelines.
Dissolution Test development in regard to bioequivalenceanezlin
The document discusses the development and use of dissolution tests in assessing bioequivalence. It describes the Biopharmaceutics Classification System which categorizes drugs based on their solubility and permeability properties. Dissolution tests are used to evaluate product quality, ensure batch-to-batch consistency, and demonstrate similarity between formulations to support biowaivers. The key factors that influence dissolution testing are discussed, including test conditions, similarity calculations, and criteria for determining equivalent dissolution profiles. Montelukast sodium, a drug with low solubility, is presented as a case study.
This quality guide provides recommendations for manufacturers of food supplements to help ensure safe and consistent production across the EU. It covers quality management systems, facilities and equipment requirements, personnel training, hazard analysis procedures, product development, manufacturing, storage, transport, documentation, complaints handling and more. The goal is to incorporate mandatory EU legal requirements as well as best practices to maintain high product quality.
This document provides the standard test method for determining the pour point of petroleum products using a manual test procedure. It defines pour point as the lowest temperature at which movement of a petroleum product is observed when cooled under controlled conditions. The test method involves cooling a sample in a test jar at a controlled rate and examining it at 3°C intervals to detect any flow or movement. The lowest temperature at which no movement is observed within 5 seconds is recorded as the pour point. Precision statements indicate that repeatability is within 3°C and reproducibility between laboratories is within 6°C for most petroleum products when following this test method.
This document discusses the process validation of capsules. It begins by providing background on validation and defining process validation according to the FDA. It then describes the three main types of process validation: prospective, concurrent, and retrospective. Key documents used in validation like the validation master plan, validation protocols and reports, and standard operating procedures are also outlined. The validation process for capsules is then detailed, including evaluating the capsule composition, selecting the encapsulation process and equipment, and testing the encapsulation step. Critical factors considered during encapsulation like the technique used and encapsulation speed are also summarized.
This document discusses the importance of preformulation studies in designing sustained release dosage forms. Preformulation studies provide important information about the drug substance that can be used to develop stable and bioavailable sustained release formulations. Key aspects of preformulation include determining solubility, pKa, partition coefficient, crystal properties, and compatibility with excipients. This information helps select appropriate formulation components, manufacturing processes, container closure systems and more. The overall goal of preformulation is to generate data to support the development of sustained release dosage forms that can be mass produced and provide a prolonged therapeutic effect.
Almac offers an accelerated drug development process that can take a lead candidate from selection to Phase I regulatory submission in just 12 months. Their integrated single-site capabilities include preclinical safety assessment studies, API and drug product development, analytical support, regulatory support, and dedicated project management. Using a single contract and commercial contact, Almac aims to reduce the effort spent on auditing, coordinating, and managing multiple vendors during the early clinical development process.
This document discusses carbon-14 labeling of peptides for use in ADME studies. It provides an overview of carbon-14, its production and starting materials. Synthetic strategies for incorporating carbon-14 into peptides are described, including direct labeling of amino acids or terminal residues. Case studies demonstrate labeling strategies for two peptides, one involving a biotinylation reaction. The document concludes that carbon-14 labeling is well-suited for assessing a drug's ADME profile and that limitations in specific activity can be overcome through accelerated mass spectrometry.
Almac provides solid state services to support drug development from invention to launch. Their services include polymorph screening and selection, crystallization development, physical form characterization, analytical method development and validation, and troubleshooting. They have highly trained scientists with the ability to solve any solid state problems. Their goal is to find and produce the optimal physical form of drugs to ensure development success.
Almac provides chemistry and manufacturing solutions for APIs from discovery through commercialization. They offer multi-purpose GMP manufacturing facilities, process R&D, preclinical through commercial API supply, analytical development and validation, potent API production, biotransformation, micronization, and process validation using quality by design approaches. Almac has expertise in chemical development, biocatalysis, physical sciences, formulation development, and analytical services to support clients' API needs.
This document summarizes the key biocatalysis services offered by Almac, including enzyme screening and process optimization, chiral building block synthesis, metabolite synthesis, and dedicated support for integrating biocatalytic technology. Almac has capabilities across enzyme selection, scale-up from grams to tons, and case studies in areas like using carbonyl reductase to synthesize chiral alcohols with high enantiomeric excess, resolving difficult alcohols with hydrolase, and producing metabolites at multi-kilogram scale for further studies. Contact information is provided for inquiries regarding Almac's biocatalysis services.
Effective process validation contributes significantly to assuring drug quality. The basic
principle of quality assurance is that a drug should be produced that is fit for its intended use.
This principle incorporates the understanding that the following conditions exist:
• Quality, safety, and efficacy are designed or built into the product.
• Quality cannot be adequately assured merely by in-process and finished-product
inspection or testing
Drug discovery process powerpoint presentation templatesSlideTeam.net
The drug discovery process involves several steps:
1) Discovery of 10,000-20,000 candidate drugs through high-throughput screening and target validation.
2) Lead optimization of candidate drugs using combinatorial chemistry and structure-based drug design.
3) ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) studies are conducted on the optimized leads.
One drug is finally approved through clinical trials and NDA (New Drug Application) approval.
This document discusses compendial testing, which involves analytical testing to prove the identity, efficacy, and safety of drug products. It provides examples of identification tests for several active pharmaceutical ingredients (APIs) and their formulated products. Identification tests may use techniques like infrared spectroscopy, thin layer chromatography, melting point determination, or X-ray diffraction to confirm the identity of an API. Tests for formulated products often involve extracting the API from the dosage form. Identification of counterions like chloride or tartrate is also sometimes required for APIs. The level of testing depends on the drug's characteristics and dosage form.
This document outlines chemistry, manufacturing, and controls (CMC) requirements for a marketing authorization application of a drug product. It identifies several areas that require further information, clarification, or validation for the drug substance, excipients, manufacturing process, process controls, specifications, and analytical procedures. Key issues noted include a lack of justification for excipient use, incomplete pharmaceutical development reports, missing process validation data, insufficient characterization of impurities, and non-compliance of some specifications and analytical methods with pharmacopeial standards. Additional data is requested to address these deficiencies before the application can be filed.
This document discusses the process validation of transdermal drug delivery systems. It begins by defining transdermal drug delivery systems as patches designed to deliver medication through the skin. It then lists some advantages and disadvantages of these systems. The document outlines the key elements that must be considered for transdermal validation, including planning, documentation, understanding processes, and communication. It describes the specific unit operations and materials used in transdermal system production like material receipt, mixing, coating, drying, laminating, and pouching. The document also discusses qualification of equipment and processes, assumptions that must be in place before validation, and the documentation required as part of the validation matrix, including the validation protocol.
A seminar on applications of various analytical techniquePatel Parth
This document provides information on preformulation studies for new drug development. It discusses:
1. The purpose of preformulation studies is to understand the characteristics of drug components and optimize dosage form manufacturing.
2. Preformulation studies establish the identity, properties, and compatibility of new drug substances to support formulation development and regulatory filings.
3. A variety of analytical techniques are used in preformulation studies including spectroscopy, chromatography, and thermal analysis to characterize drug substances and excipients.
This document discusses process validation for liquid oral dosage forms. It defines process validation and explains that it ensures consistent production of products meeting quality standards. The objectives are to assure product quality and reduce batch variation. Types of liquid orals include solutions, suspensions, and emulsions. Critical process parameters for equipment, processing, and acceptance criteria are identified. The validation operations described include testing of raw materials and monitoring of outputs like appearance, pH, and content uniformity. A validation report is prepared and changes may require revalidation.
The document discusses pharmaceutical product development and regulation. It addresses what information a regulatory authority would need to see if someone claims to have discovered a new drug or developed a generic version of an existing drug. It explains the importance of absorption and bioavailability/bioequivalence testing. It also presents scenarios about an innovator changing a drug's formulation, manufacturing site, process, or equipment and asks what type of studies would be required. The overall message is that understanding a product, controlling the manufacturing process, and demonstrating consistent quality and therapeutic effect through clinical and comparative dissolution studies are crucial aspects of drug regulation.
This document provides test methods for analyzing phthalate content in children's products used by the U.S. Consumer Product Safety Commission (CPSC). It describes sample preparation, phthalate extraction, gas chromatography-mass spectrometry operating procedures, quality control measures, and calculations for determining phthalate concentration. Comments on the methods are encouraged by March 31, 2009. The general approach is to grind samples, dissolve in solvents, filter, dilute, and analyze by GC-MS, integrating peak areas to quantify six regulated phthalates.
The principal objective of dosage form design is to
achieve a predictable therapeutic response to a drug
included in a formulation which is capable of large scale
manufacture with reproducible product quality. To ensure
product quality, numerous features are required, like
chemical and physical stability, suitable preservation
against microbial contamination if appropriate,
uniformity of dose of drug, acceptability to users
including prescriber and patient, as well as suitable
packing, labeling, and validation1
.
Process validation establishes the flexibility and
constraints in the manufacturing process controls in the
attainment of desirable attributes in the drug product
while preventing undesirable properties. This is an
important concept, since it serves to support the
underlying definition of validation, which is a systematic
approach to identifying, measuring, evaluating,
documenting, and re-evaluating a series of critical steps in
the manufacturing process that require control to ensure
a reproducible final product.3
USFDA defined process validation as “establishing
documented evidence which provides high degree of
assurance that a specific process will consistently produce
a product meeting its pre determined specifications and
quality characteristics.”5
Solid dosage forms include tablets and capsules. The
manufacturing of solid dosage forms involves extensive
powder handling. The powder must be blended for
uniformity and converted into the dosage form either
through compression or encapsulation. Typical
requirements include weighing, blending,
mixing/granulation areas, compression/encapsulation
areas, and coating areas. 2
Despite the ongoing development of more sophisticated
solid drug delivery systems, tablets are still by far the
most prevalent solid dosage form. The emphasis will be
on the practical inspectional requirement, rather than on
a theoretical approach that does not reflect the
practicalities (and problems) encountered when
validating actual production operations.
A tablet is a pharmaceutical dosage form. It comprises a
mixture of active substances and excipients, usually in
powder form, pressed or compacted into a solid. The
excipients can include binders, glidants (flow aids) and
lubricants to ensure efficient tabletting; disintegrants to
promote tablet break-up in the digestive tract;
sweeteners or flavors to enhance taste; and pigments to
make the tablets visually attractive. A polymer coating is
often applied to make the tablet smoother and easier to
swallow, to control the release rate of the active
ingredient, to make it more resistant to the environment
(extending its shelf life), or to enhance the tablet's
appearance
FDA container closure system & drug stability saurav anand 23 iiphncsaurav
The document provides guidelines on container closure systems for packaging drugs and their stability according to FDA regulations. It defines packaging components and discusses CGMP, CPSC, and USP requirements. The guidelines specify information to submit to the FDA regarding packaging qualification, drug dosage forms, and extraction studies. It also addresses post-approval packaging changes, drug master files, bulk containers, and factors that influence drug stability as per ICH guidelines.
Dissolution Test development in regard to bioequivalenceanezlin
The document discusses the development and use of dissolution tests in assessing bioequivalence. It describes the Biopharmaceutics Classification System which categorizes drugs based on their solubility and permeability properties. Dissolution tests are used to evaluate product quality, ensure batch-to-batch consistency, and demonstrate similarity between formulations to support biowaivers. The key factors that influence dissolution testing are discussed, including test conditions, similarity calculations, and criteria for determining equivalent dissolution profiles. Montelukast sodium, a drug with low solubility, is presented as a case study.
This quality guide provides recommendations for manufacturers of food supplements to help ensure safe and consistent production across the EU. It covers quality management systems, facilities and equipment requirements, personnel training, hazard analysis procedures, product development, manufacturing, storage, transport, documentation, complaints handling and more. The goal is to incorporate mandatory EU legal requirements as well as best practices to maintain high product quality.
This document provides the standard test method for determining the pour point of petroleum products using a manual test procedure. It defines pour point as the lowest temperature at which movement of a petroleum product is observed when cooled under controlled conditions. The test method involves cooling a sample in a test jar at a controlled rate and examining it at 3°C intervals to detect any flow or movement. The lowest temperature at which no movement is observed within 5 seconds is recorded as the pour point. Precision statements indicate that repeatability is within 3°C and reproducibility between laboratories is within 6°C for most petroleum products when following this test method.
This document discusses the process validation of capsules. It begins by providing background on validation and defining process validation according to the FDA. It then describes the three main types of process validation: prospective, concurrent, and retrospective. Key documents used in validation like the validation master plan, validation protocols and reports, and standard operating procedures are also outlined. The validation process for capsules is then detailed, including evaluating the capsule composition, selecting the encapsulation process and equipment, and testing the encapsulation step. Critical factors considered during encapsulation like the technique used and encapsulation speed are also summarized.
This document discusses the importance of preformulation studies in designing sustained release dosage forms. Preformulation studies provide important information about the drug substance that can be used to develop stable and bioavailable sustained release formulations. Key aspects of preformulation include determining solubility, pKa, partition coefficient, crystal properties, and compatibility with excipients. This information helps select appropriate formulation components, manufacturing processes, container closure systems and more. The overall goal of preformulation is to generate data to support the development of sustained release dosage forms that can be mass produced and provide a prolonged therapeutic effect.
Almac offers an accelerated drug development process that can take a lead candidate from selection to Phase I regulatory submission in just 12 months. Their integrated single-site capabilities include preclinical safety assessment studies, API and drug product development, analytical support, regulatory support, and dedicated project management. Using a single contract and commercial contact, Almac aims to reduce the effort spent on auditing, coordinating, and managing multiple vendors during the early clinical development process.
This document discusses carbon-14 labeling of peptides for use in ADME studies. It provides an overview of carbon-14, its production and starting materials. Synthetic strategies for incorporating carbon-14 into peptides are described, including direct labeling of amino acids or terminal residues. Case studies demonstrate labeling strategies for two peptides, one involving a biotinylation reaction. The document concludes that carbon-14 labeling is well-suited for assessing a drug's ADME profile and that limitations in specific activity can be overcome through accelerated mass spectrometry.
Almac provides solid state services to support drug development from invention to launch. Their services include polymorph screening and selection, crystallization development, physical form characterization, analytical method development and validation, and troubleshooting. They have highly trained scientists with the ability to solve any solid state problems. Their goal is to find and produce the optimal physical form of drugs to ensure development success.
Almac provides chemistry and manufacturing solutions for APIs from discovery through commercialization. They offer multi-purpose GMP manufacturing facilities, process R&D, preclinical through commercial API supply, analytical development and validation, potent API production, biotransformation, micronization, and process validation using quality by design approaches. Almac has expertise in chemical development, biocatalysis, physical sciences, formulation development, and analytical services to support clients' API needs.
This document summarizes the key biocatalysis services offered by Almac, including enzyme screening and process optimization, chiral building block synthesis, metabolite synthesis, and dedicated support for integrating biocatalytic technology. Almac has capabilities across enzyme selection, scale-up from grams to tons, and case studies in areas like using carbonyl reductase to synthesize chiral alcohols with high enantiomeric excess, resolving difficult alcohols with hydrolase, and producing metabolites at multi-kilogram scale for further studies. Contact information is provided for inquiries regarding Almac's biocatalysis services.
This document discusses site-specific protein modification using Almac's proprietary protein ligation technology. The technology enables proteins to be modified at their C-terminus in a highly selective and high-yielding manner, resulting in homogeneous conjugated protein products with retained biological activity. This overcomes limitations of existing nonspecific protein modification methods. The technology has been demonstrated on various therapeutic proteins and can attach a wide range of labels and molecules like PEG for half-life extension.
This document discusses strategies for solid phase peptide synthesis (SPPS) using different protecting groups. It compares the t-Boc and Fmoc protection methods, noting the advantages of Fmoc such as using milder acidic conditions for deprotection and cleavage from the resin. Protocols are provided for various steps in Fmoc SPPS including resin loading, amino acid coupling and deprotection, and final cleavage and deprotection. Potential side reactions are also described such as diketopiperazine formation and aspartimide formation, along with ways to prevent these reactions.
Almac provides radiolabeling services including the synthesis of 14C labeled APIs and drug products for human ADME studies. They have a 14C manufacturing license and cGMP compliance. Almac uses integrated teams of radiochemists and analytical experts along with state-of-the-art facilities to efficiently develop and manufacture radiolabeled compounds. Case studies demonstrate successful projects involving peptide radiolabeling and developing powder-filled capsules and sterile solutions for clinical studies.
Almac provides services related to peptide synthesis and protein engineering including GMP manufacturing for clinical trials, a chemokine catalogue, fluorescence lifetime assays, and proprietary technologies for site-specific protein modification. They offer a complete package for first-in-man clinical trials including chemical and analytical development, material supply, oversight of formulation and clinical trials. Case studies demonstrate their work synthesizing modified chemokines and developing sterile drug products for clinical use.
Innovative Drug Pipeline Solutions: Medicinal Chemistry, Process Chemistry, cGMP API Manufacturing. 105+ global clients. 120,000 sq.ft. facilities located in Research Triangle Park, NC USA. FDA inspected and DEA registered.
EFRAC is an ISO 17025 accredited pharmaceutical testing facility located in Chennai, India. It has 11 regulatory accreditations and conducts a wide range of tests for drugs, cosmetics, and related products according to international standards. EFRAC utilizes cutting-edge technology and qualified instrumentation to provide precise, reliable, and legally defensible testing data to clients.
The SCYNEXIS analytical research and development team consists of experienced scientists who develop and validate analytical methods for starting materials, active pharmaceutical ingredients, and synthetic intermediates according to regulatory guidance documents. SCYNEXIS has state-of-the-art instrumentation and the expertise to solve complex analytical problems and meet aggressive timelines. Their services include method development and validation, assay testing, forced degradation studies, and structural identification.
Bilcare provides clinical research and development, analytical, and formulation services for pharmaceutical products. They offer technical support and GMP-qualified scientists during product development and manufacturing. Their services include pre-formulation studies, clinical trial supplies manufacturing, analytical testing from method development through stability studies, and management of controlled substances. Bilcare ensures products meet international regulatory standards through quality review of all documentation.
Therapure leverages its extensive experience & fully equipped analytical development control testing space to create robust and reliable analytical methods. Our expertise: Protein Characterization, Physiochemical analysis, Microbiological testing, etc.
Validation of analytical methods involves establishing documented evidence that a process will consistently produce results meeting predetermined specifications. It is necessary to ensure customer satisfaction, comply with regulations, and control costs. Proper documentation of validation activities includes validation master plans, protocols, and reports. Types of validation include process, cleaning, equipment, and validation of analytical methods itself. Method validation parameters that must be checked include selectivity, precision, accuracy, linearity, range, limit of detection, limit of quantification, and robustness. Validation ensures process efficiency and quality for the pharmaceutical industry.
Validation of analytical methods involves establishing documented evidence that a process will consistently produce results meeting predetermined specifications. It is necessary to ensure customer satisfaction, comply with regulations, and control costs. Proper documentation of validation activities includes validation master plans, protocols, and reports. Types of validation include process, cleaning, equipment, and validation of analytical methods itself. Method validation parameters that must be checked include selectivity, precision, accuracy, linearity, range, limit of detection, limit of quantification, and robustness. Validation ensures process efficiency and quality for the pharmaceutical industry.
Validation of analytical methods involves establishing documented evidence that a process will consistently produce results meeting predetermined specifications. It is necessary to ensure customer satisfaction, comply with regulations, and control costs. Proper documentation of validation activities includes validation master plans, protocols, and reports. Types of validation include process, cleaning, equipment, and validation of analytical methods itself. Method validation parameters that must be checked include selectivity, precision, accuracy, linearity, range, limit of detection, limit of quantification, and robustness. Validation ensures process efficiency and quality for the pharmaceutical industry.
ANALYTICAL METHOD VALIDATION BY P.RAVISANKAR Dr. Ravi Sankar
This document discusses analytical method validation. It begins with an introduction that defines validation and discusses its importance and regulatory requirements. The document then covers specific validation parameters such as specificity, linearity, accuracy, precision, limit of detection, limit of quantification and more. For each parameter, the document provides definitions, procedures for evaluation, and acceptance criteria. It emphasizes that validation demonstrates a method is suitable for its intended purpose and supports the identity, quality, purity and potency of drug substances and products. The overall summary is that analytical method validation is critical to ensure quality and compliance in the pharmaceutical industry.
This presentation from the Institute of Validation Technology's 7th Annual Method Validation covers regulatory expectations for deviations and out-of-specification results and protocol exceptions, change control, handing investigations and CAPAs, and avoiding common pitfalls.
Good Laboratroy Practices for Pharmaceutical Laboratory.pptxnafeesa Hanif
This document is a presentation submitted by the Biochem Warriors group to Dr. Nafeesa Qudsia Hanif for the BCH-602 course. The presentation covers various topics related to pharmaceutical quality control laboratories including the role of quality control in the pharmaceutical industry, good laboratory practices, required certifications, and quality assurance and quality control processes. It is divided into several sections with group members assigned to specific topics.
QA and QC are related but distinct concepts in quality management. QA refers to the overall system that aims to prevent defects through processes, while QC tests products to identify defects. QA is a preventative system involving all employees to ensure quality standards are met throughout development. In contrast, QC is reactive and conducted by a specialized team to detect defects in finished products before release. Both work together to continually meet customer requirements, with QA focusing on building quality in from the start and QC checking for quality along the way.
Definition
Scope of calibration
Scope of validation
Frequency of calibration
Importance/ purpose of calibration
Importance/ advantages of validation
Difference between calibration & validation
Pharmaceutical Validation: Role in Phamaceutical Industrykaunainfathema1
This is a brief presentation on various concepts under Pharamaceutical Validation including its importance, scope, history, authorities, types of validation, VMP; along with the ICH and WHO Guidelines to be followed for Calibration of Equipments.
1. Analytical Services
Meeting your analytical needs throughout drug development.
> API and Drug Product Testing
> Analytical Support for Clinical Trials
> Comparator Testing
> Physical and Chemical Characterisation
> Method Development and Validation
> ICH Stability Testing
Analytical Services
www.almacgroup.com
2. Commercial Services
Analytical Services
Clinical Technologies
Meeting your analytical needs throughout drug development.
From our state-of-the-art analytical laboratories, our highly skilled analysts deliver comprehensive
analytical solutions to support your drug substance and drug product development programmes, as well
as providing analytical and microbiological testing solutions for clinical and commercial drug product
Clinical Trial Supply
supply. Employing over 150 analysts at one site, we examine your drug substance and drug products
chemical, physical and microbiological properties to support clinical manufacturing, commercial release,
and stand-alone analytical projects.
Analytical Services
Product Testing
> API
Method Development & Validation
> Assay
Analytical Support to Clinical Trial Supplies
> Drug product > Related substances
Almac can provide the necessary on-site analytical support for all your clinical packaging projects and
Pharmaceutical Development
> Clinical trial material > Dissolution
> Comparator > Cleaning verification beyond. Our dedicated analytical chemists provide information rich data on both comparator and
> Stability indicating
innovator material in full compliance with regulatory requirements.
Comparator Testing > Bioanalysis
> Method development and validation
> Comparator dissolution Stability Testing
> Stability API and Drug Product
> Accelerated and long-term
studies at all ICH conditions Capabilities:
Physical Characterisation
> Polymorph screening > Protocol and report preparation > Identification / Absence of active
API Services & Chemical Development
> Intrinsic dissolution > Elucidation of degradation pathways > Characterisation
> Thermal properties > Identification of degradants > Release testing of IMPs
> Particle morphology > Synthesis of degradants > Comparator studies
> Method transfer
Chemical Characterisation > Method development
> Proof of structure > Method verification or validation
> Identification of impurities > Stability testing
> Identification of degradants > Re-assay
> Identification of metabolites
Biomarker Discovery & Development
Our method development team routinely work with challenging drug molecules in order to establish
fit-for-purpose methods utilising cutting edge technology. This enables our customers to benefit from having the
right data, at the right time, to the highest standards. Almac’s highly experienced stability testing group provides
a turn-key service encompassing protocol writing, sample labelling and storage, study management, analytical
testing and report writing. Unique to Almac is the ability to identify, isolate and synthesize degradation products
that may form on storage.
3. www.almacgroup.com
Commercial Services
Comparator Studies
Comparator activities Active and Placebo activities
Clinical Technologies
> Develop and validate analytical methods > Cleaning analytical method verification
> Structure elucidation of organic > Validation / transfer of drug product
impurities analytical methods
> Over-encapsulated comparator stability > Manufacture technical batch of customers’
profile active tablet formulation
Clinical Trial Supply
> Manufacture and release of GMP > Manufacture and release clinical batch of
batches of over-encapsulated comparator customers’ active tablet formulation
> Manufacture and release of placebo tablets
> Manufacture and release of over-encapsulated
active tablets
> ICH stability
Analytical Services
Comparator Products
Pharmaceutical Development
> Penicillin VK > Hydroxychlorquine Sulphate > Formoterol
> Morphine Sulphate ER > Levofloxacin > Aspirin
> Morphine Sulphate IR > Carbamaxepine > Omeprazole
> Oxycodone > Trimethobenzamide > Minocyline
> Simvastatin > Telithromycin > Isosorbide-5-mononitrate
> Pravastatin > Zolpidem Tartrate
> Atorvastatin > Glipizide
> Warfarin Sodium > Budesonide
API Services & Chemical Development
Equipment Capabilities
> HPLC > LC-MSn > NMR > Microscopy
> UPLC > GC-MS > FTIR > Particle Sizing
> Ion Chromatography > MALDI-TOF > UV > DSC
> GC > Polarimetry > TGA
Biomarker Discovery & Development
> GC-HS > DVS
> Dissolution
For European Enquiries: For American Enquiries:
Almac Almac Group Incorporated
Almac House 25 Fretz Road
20 Seagoe Industrial Estate, Souderton, PA 18964
Craigavon, BT63 5QD, United States of America
United Kingdom. T +1 (215) 660 8500
T: +44 (0) 28 3833 2200 E: sciences@almacgroup.com
E: sciences@almacgroup.com
www.almacgroup.com